# An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy

> **NCT00004978** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 4150 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Recombinant interleukin-2 (rIL-2)

## Key facts

- **NCT ID:** NCT00004978
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-03
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 4150 (ACTUAL)
- **Last updated:** 2021-11-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004978, "An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00004978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*